Two Women Fell Sick From the Coronavirus. One Survived. – The New York Times

The young mothers didnt tell their children they had the coronavirus. Mama was working hard, they said, to save sick people.

Instead, Deng Danjing and Xia Sisi were fighting for their lives in the same hospitals where they worked, weak from fever and gasping for breath. Within a matter of weeks, they had gone from healthy medical professionals on the front lines of the epidemic in Wuhan, China, to coronavirus patients in critical condition.

The world is still struggling to fully understand the new virus, its symptoms, spread and sources. For some, it can feel like a common cold. For others, it is a deadly infection that ravages the lungs and pushes the immune system into overdrive, destroying even healthy cells. The difference between life and death can depend on the patients health, age and access to care although not always.

The virus has infected more than 132,000 globally. The vast majority of cases have been mild, with limited symptoms. But the viruss progression can be quick, at which point the chances of survival plummet. Around 68,000 people have recovered, while nearly 5,000 have died.

The fates of Ms. Deng and Dr. Xia reflect the unpredictable nature of a virus that affects everyone differently, at times defying statistical averages and scientific research.

As the new year opened in China, the women were leading remarkably similar lives. Both were 29 years old. Both were married, each with a young child on whom she doted.

Ms. Deng, a nurse, had worked for three years at Wuhan No. 7 Hospital, in the city where she grew up and where the coronavirus pandemic began. Her mother was a nurse there, too, and in their free time they watched movies or shopped together. Ms. Dengs favorite activity was playing with her two pet kittens, Fat Tiger and Little White, the second of which she had rescued just three months before falling sick.

Before the epidemic, Ms. Deng had promised to take her 5-year-old daughter to the aquarium.

Dr. Xia, a gastroenterologist, also came from a family of medical professionals. As a young child, she had accompanied her mother, a nurse, to work. She joined the Union Jiangbei Hospital of Wuhan in 2015 and was the youngest doctor in her department. Her colleagues called her Little Sisi or Little Sweetie because she always had a smile for them. She loved Sichuan hot pot, a dish famous for its numbingly spicy broth.

Dr. Xia loved traveling with her family. She had recently visited Wuzhizhou Island, a resort destination off the southern coast of China.

When a mysterious new virus struck the city, the women began working long hours, treating a seemingly endless flood of patients. They took precautions to protect themselves. But they succumbed to the infection, the highly contagious virus burrowing deep into their lungs, causing fever and pneumonia. In the hospital, each took a turn for the worse.

One recovered. One did not.

Onset of virus & hospitalization

Ms. Deng, a Wuhan native who liked makeup and hanging out with her friends at Starbucks, had worked for eight years as a nurse, following her mothers career path. Dr. Xia, who was a favorite among elderly patients, spent long hours at the hospital helping to treat people suspected of having the virus.

The symptoms came on suddenly.

Dr. Xia had ended her night shift on Jan. 14 when she was called back to attend to a patient a 76-year-old man with suspected coronavirus. She dropped in frequently to check in on him.

Five days later, she started feeling unwell. Exhausted, she took a two-hour nap at home, then checked her temperature: It was 102 degrees. Her chest felt tight.

A few weeks later, in early February, Ms. Deng, the nurse, was preparing to eat dinner at the hospital office, when the sight of food left her nauseated. She brushed the feeling aside, figuring she was worn out by work. She had spent the beginning of the outbreak visiting the families of confirmed patients and teaching them to disinfect their homes.

After forcing down some food, Ms. Deng went home to shower, and then, feeling groggy, took a nap. When she woke up, her temperature was 100 degrees.

Fever is the most common symptom of the coronavirus, seen in nearly 90 percent of patients. About a fifth of people experience shortness of breath, often including a cough and congestion. Many also feel fatigued.

Both women rushed to see doctors. Chest scans showed damage to their lungs, a tell-tale sign of the coronavirus that is present in at least 85 percent of patients, according to one study.

In particular, Ms. Dengs CT scan showed what the doctor called ground-glass opacities on her lower right lung hazy spots that indicated fluid or inflammation around her airways.

The hospital had no space, so Ms. Deng checked into a hotel to avoid infecting her husband and 5-year-old daughter. She sweated through the night. At one point, her calf twitched. In the morning, she was admitted to the hospital. Her throat was swabbed for a genetic test, which confirmed she had the coronavirus.

Her room in a newly opened staff ward was small, with two cots and a number assigned to each one. Ms. Deng was in bed 28. Her roommate was a colleague who had also been diagnosed with the virus.

At Jiangbei Hospital, 18 miles away, Dr. Xia was struggling to breathe. She was placed in an isolation ward, treated by doctors and nurses who wore protective suits and safety goggles. The room was cold.

Day 1, hospitalization begins

After Ms. Deng was admitted to the hospital, she told her husband to take care of himself, reminding him of the 14-day incubation period for the virus. He assured her his temperature was normal. Dr. Xia asked her husband about the possibility of getting off oxygen therapy soon. He responded optimistically.

When Ms. Deng checked into the hospital, she tried to stay upbeat. She texted her husband, urging him to wear a mask even at home, and to clean all their bowls and chopsticks with boiling water or throw them out.

Her husband sent a photograph of one of their cats at home. Waiting for you to come back, he said.

I think itll take 10 days, half a month, she replied. Take care of yourself.

There is no known cure for Covid-19, the official name for the disease caused by the new coronavirus. So doctors rely on a cocktail of other medicines, mostly antiviral drugs, to alleviate the symptoms.

Ms. Dengs doctor prescribed a regimen of arbidol, an antiviral medicine used to treat the flu in Russia and China; Tamiflu, another flu medicine more popular internationally; and Kaletra, an HIV medicine thought to block the replication of the virus. Ms. Deng was taking at least 12 pills a day, as well as traditional Chinese medicine.

Arbidol, an antiviral medication, was prescribed to help alleviate Ms. Dengs symptoms.

Despite her optimism, she grew weaker. Her mother delivered home-cooked food outside the ward, but she had no appetite. To feed her, a nurse had to come at 8:30 each morning to hook her up to an intravenous drip with nutrients. Another drip pumped antibodies into her bloodstream, and still another antiviral medicine.

Dr. Xia, too, was severely ill, but appeared to be slowly fighting the infection. Her fever had subsided after a few days, and she began to breathe more easily after being attached to a ventilator.

Her spirits lifted. On Jan. 25, she told her colleagues she was recovering.

I will return to the team soon, she texted them on WeChat.

We need you the most, one of her colleagues responded.

In early February, Dr. Xia asked her husband, Wu Shilei, also a doctor, whether he thought she could get off oxygen therapy soon.

Take it easy. Dont be too anxious, he replied on WeChat. He told her that the ventilator could possibly be removed by the following week.

I keep on thinking about getting better soon, Dr. Xia responded.

There was reason to believe she was on the mend. After all, most coronavirus patients recover.

Later, Dr. Xia tested negative twice for the coronavirus. She told her mother she expected to be discharged on Feb. 8.

Day 4 to 16 after hospitalization

In the hospital, Ms. Dengs only contacts were her roommate and the medical staff. She added a caption to a photo with her doctor, saying laughter would help chase the illness away. Two tests indicated that Dr. Xia was free of the virus, but her condition suddenly deteriorated.

By Ms. Dengs fourth day in the hospital, she could no longer pretend to be cheerful. She was vomiting, having diarrhea and relentlessly shivering.

Her fever jumped to 101.3 degrees. Early in the morning on Feb. 5, she woke from a fitful sleep to find the medicine had done nothing to lower her temperature. She cried. She said she was classified as critically ill.

The next day, she threw up three times, until she was left spitting white bubbles. She felt she was hallucinating. She could not smell or taste, and her heart rate slowed to about 50 beats per minute.

On a phone call, Ms. Dengs mother tried to reassure her that she was young and otherwise healthy, and that the virus would pass like a bad cold. But Ms. Deng feared otherwise. I felt like I was walking on the edge of death, she wrote in a social media post from her hospital bed the next day.

China defines a critically ill patient as someone with respiratory failure, shock or organ failure. Around 5 percent of infected patients became critical in China, according to one of the largest studies to date of coronavirus cases. Of those, 49 percent died. (Those rates may eventually change once more cases are examined around the world.)

While Dr. Xia appeared to be recovering, she was still terrified of dying. Testing can be faulty, and negative results dont necessarily mean patients are in the clear.

She asked her mother for a promise: Could her parents look after her 2-year-old son if she didnt make it?

Hoping to dispel her anxiety with humor, her mother, Jiang Wenyan, chided her: Hes your own son. Dont you want to raise him yourself?

Dr. Xia also worried about her husband. Over video chat, she urged him to put on protective equipment at the hospital where he worked. She said she would wait for me to return safely, he said, and go to the frontline again with me when she recovered.

Then came the call. Dr. Xias condition had suddenly deteriorated. In the early hours of Feb. 7, her husband rushed to the emergency room.

Her heart had stopped.

Day 17 after hospitalization

After being discharged, Ms. Deng briefly got to see her mother, who had been working at the hospital during her illness. She then went home to isolate herself for two weeks.

In most cases, the body repairs itself. The immune system produces enough antibodies to clear the virus, and the patient recovers.

By the end of Ms. Dengs first week in the hospital, her fever had receded. She could eat the food her mother delivered. On Feb. 10, as her appetite returned, she looked up photos of meat skewers online and posted them wishfully to social media.

On Feb. 15, her throat swab came back negative for the virus. Three days later, she tested negative again. She could go home.

Ms. Deng met her mother briefly at the hospitals entrance. Then, because Wuhan remained locked down, without taxis or public transportation, she walked home alone.

I felt like a little bird, she recalled. My freedom had been returned to me.

She had to isolate at home for 14 days. Her husband and daughter stayed with her parents.

At home, she threw out her clothing, which she had been wearing for her entire time in the hospital.

Since then, she has passed the time by playing with her cats and watching television. She jokes that she is getting an early taste of retirement. She does daily deep breathing exercises to strengthen her lungs, and her cough has faded.

The Chinese government has urged recovered patients to donate plasma, which experts say contains antibodies that could be used to treat the sick. Ms. Deng contacted a local blood bank soon after getting home.

She plans to go back to work as soon as the hospital allows it.

It was the nation that saved me, she said. And I think I can pay it back to the nation.

Day 35 after hospitalization

On Dr. Xias desk at work, her colleagues left 1,000 paper cranes a Chinese symbol of hope and blessings. Written on the wings was a message: Rest in peace, we will use our lives to continue this relay race and prevail over this epidemic.

It was sometime after 3 a.m. on Feb. 7 when Dr. Xia was rushed to intensive care. Doctors first intubated her. Then, the president of the hospital frantically summoned several experts from around the city, including Dr. Peng Zhiyong, head of the department of critical care at Zhongnan Hospital.

They called every major hospital in Wuhan to borrow an extracorporeal membrane oxygenation, or Ecmo, machine to do the work of her heart and lungs.

Dr. Xias heart started beating again. But the infection in her lungs was too severe, and they failed. Her brain was starved of oxygen, causing irreversible damage. Soon, her kidneys shut down and doctors had to put her on round-the-clock dialysis.

The brain acts as the control center, Dr. Peng said. She couldnt command her other organs, so those organs would fail. It was only a matter of time.

Dr. Xia slipped into a coma. She died on Feb. 23.

Dr. Peng remains baffled about why Dr. Xia died after she had seemed to improve. Her immune system, like that of many health workers, may have been compromised by constant exposure to sickness. Perhaps she suffered from what experts call a cytokine storm, in which the immune systems reaction to a new virus engulfs the lungs with white blood cells and fluid. Perhaps she died because her organs were starved of oxygen.

Back at Dr. Xias home, her son, Jiabao which means priceless treasure still thinks his mother is working. When the phone rings, he tries to grab it from his grandmothers hands, shouting: Mama, mama.

Her husband, Dr. Wu, doesnt know what to tell Jiabao. He hasnt come to terms with her death himself. They had met in medical school and were each others first loves. They had planned to grow old together.

I loved her very much, he said. Shes gone now. I dont know what to do in the future, I can only hold on.

Go here to read the rest:

Two Women Fell Sick From the Coronavirus. One Survived. - The New York Times

Why There Aren’t Enough Coronavirus Tests in the U.S. – Popular Mechanics

Above: A researcher works in a lab that is developing testing for the COVID-19 coronavirus at Hackensack Meridian Health Center for Discovery and Innovation on February 28, 2020 in Nutley, New Jersey. (Photo by Kena Betancur/Getty Images)

There's a massive shortage of COVID-19 (Coronavirus) test kits in the U.S., as cases continue to skyrocket in places like Seattle and New York City. This is largely due to the failure of the Centers for Disease Control and Prevention (CDC) to distribute the tests in a timely fashion.

But it didn't have to be this way. Back in January and Februarywhen cases of the deadly disease began aggressively circulating outside of Chinadiagnostics already existed in places like Wuhan, where the pandemic began. Those tests followed World Health Organization (WHO) test guidelines, which the U.S. decided to eschew.

Instead, the CDC created its own in-depth diagnostics that could identify not only COVID-19, but a host of SARS-like coronaviruses. Then, disaster struck: When the CDC sent tests to labs during the first week of February, those labs discovered that while the kits did detect COVID-19, they also produced false positives when checking for other viruses. As the CDC went back to the drawing board to develop yet more tests, precious time ticked away.

"I think that we should have had testing more widely available about a month earlier," Dr. Carl Fichtenbaum, professor of clinical medicine at the University of Cincinnati's School of Medicine, tells Popular Mechanics. "That would have been more appropriate so that we could have identified people earlier on and used some of the mitigating strategies that were using now."

As the spread of Coronavirus continues to escalate in the U.S., private institutions like academic research hospitals are scrambling in a mad dash to come up with more test kits. And there is hope: The Cleveland Clinic says it has developed a diagnostic test that can deliver results in just hours, as opposed to the time it takes the existing CDC tests, which can take days.

WPA PoolGetty Images

Testing for COVID-19 comes in two primary forms: You'll either have your throat swabbed if you're in the U.S., or perhaps have your blood drawn if you're in another country, like China. The different approaches ultimately come down to how scientists have developed the lab tests.

In the U.S., the CDC's diagnostic tool relies on polymerase chain reaction testing (PCR), which detects genetic material found in the virus's RNA. Unlike in other methods, the virus doesn't have to be alive for its presence to be detected.

"We take parts of the virus and we [test] whats called the conserved parts of the virus, parts that dont change a lot," Dr. Fichtenbaum explains. "There are always mutations. Were looking at the genetic code and we take a sequence of what we call primers, or things that will match up with that genetic code, and we put them through a series of steps where the primers will match the genetic code if [the virus] is present."

PCR testing is generally too advanced to be done at a hospital, and is more in the wheelhouse of clinical laboratory settings. There, researchers extract the sample's nucleic acidone of the four bases found in DNA sequencesto study the virus genome. They can amplify portions of that genome through a special process called reverse transcription polymerase chain reaction. That way, scientists can compare the sample to SARS-CoV-2, the virus that causes the novel coronavirus.

SARS-CoV-2 has almost 30,000 nucleotides in total, which make up its DNA. The University of Washington School of Medicine's PCR test hones in on about 100 of those that are known to be unique to the virus.

The researchers are looking for two genes in particular, and if they find both, the test is considered positive. If they only find one, the test is inconclusive. However, the CDC notes, "it is possible the virus will not be detected" in the early stages of the viral infection.

In some cases, Dr. Fichtenbaum says, it's possible to quantify the number of copies of the viral gene present. It could be one, 10, or 10 million, he says, and the higher that amount is, the more contagious you may be, or the further along you may be in the illness.

U.S. Centers for Disease Control and Prevention

As of press time, the CDC has directly examined some 3,791 specimens in Atlanta, according to data produced on Thursday afternoon, while public health laboratories across the country have tested another 7,288. Notably, some data after March 6 is still pending.

Regardless, with about 1,000 confirmed cases in the U.S., those figures suggest roughly one in 11 people tested have actually contracted the novel Coronavirus. Surely, if more tests were available, those numbers would be higher, Dr. Fichtenbaum says. Because of the CDC snafu and an initial muted reaction to the outbreak from President Trump's administration, we're about a month behind on the diagnostics front, he adds.

Piling onto other reasons, Dr. Karen C. Carrolldirector of the Division of Medical Microbiology at Johns Hopkins University School of Medicinebelieves that the test shortage is "complicated" by the fact that no one expected COVID-19 to spread so quickly in the U.S.

Not to mention, manufacturers are now low on supplies that academic labs, like hers, require to develop and distribute test kits, she tells Popular Mechanics.

During a Congressional hearing on Wednesday, Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said the public health care system is failing to make tests available to people who may have contracted COVID-19.

"The idea of anybody getting [the test] easily the way people in other countries are doing it, we're not set up for that. Do I think we should be? Yes, but we're not," he said.

The silver lining: The CDC is now working in tandem with private labs to make more tests available. The concern then becomes how many tests these labs can actually perform each day. Experts estimate that most labs will have the capacity to complete about 100 tests per day, which just isn't good enough to contain COVID-19 at this point.

China News ServiceGetty Images

Just because your doctor may have ordered you a COVID-19 test, that doesn't mean you'll actually receive one.

According to CDC guidelines, there are three general classes of patients who seek the diagnostic test, and it's up to the discretion of the health care systems to administer them. With limited supply, those are tough decisions. The classes are:

Testing can be quite restrictive, and people who aren't in a high risk category, or who have traveled to a country where there are cases of COVID-19but had no known exposure to the virusare turned away.

"Once we relax the standards for testing so that we can test on anyone we think appropriate, and its not as complicated, we'll be able to reduce the spread," Dr. Fichtenbaum says.

Right now in Ohio, where Dr. Fichtenbaum is based, doctors must fill out a four-page form and conduct in-depth tracing of a patient's movements before they can administer a test, he says. Not only is it time-consuming, but it may result in the patient not receiving a test at alland could have contracted the virus.

THOMAS KIENZLEGetty Images

To expedite the availability of diagnostics, the U.S. Food and Drug Administration (FDA) announced in late February that academic hospital systems had the green light to develop their own test kits.

The move allows these institutions to rely on their own internal validation upfront, rather than wait on the time-consuming FDA approvals process before using the tests. While FDA approval is still ultimately required under this policy, once the hospitals themselves have determined the tests are accurate and safe, they can begin using them.

Dr. Carroll of Johns Hopkins says that her lab went live with their own test yesterday. "Now, we have 15 days to send [the FDA] our validation package," she says. Her lab can now use the test to check for COVID-19 in patients that come to the medical center, but a few more things must also happen in tandem to satisfy the FDA's requirements.

Once a private lab sends in their validation package, which includes data collected during the test development, the FDA may call back with questions about the kit or ask for clarification. If the labs get radio silence for a while, that's normal, according to Dr. Carroll, but eventually, they must be granted what is known as an Emergency Use Authorization.

Under section 564 of the Federal Food, Drug, and Cosmetic Act, the FDA Commissioner may allow unapproved medical productslike privately developed COVID-19 teststo be used in an emergency for diagnosis, treatment or prevention when there are no better alternatives.

"I dont know how quickly they will get back to laboratories, they havent told us that," Dr. Carroll says.

Labs must also have close communication with their state health department laboratory, which is essentially the top lab in the state, she added. The FDA is requiring private institutions to send their first five negative and first five positive testing results to their state lab to ensure uniformity and effectiveness.

"A public health laboratory monitors certain communicable diseases," Dr. Carroll explains. "Some even offer testing for the community, like STDs such as Gonorrhea."

Other hospitals across the U.S. are making strides in test development, too. In Washington, where the CDC's faulty tests stymied the progress of testing, potentially aiding the community spread seen there, the University of Washington Medical Center has developed a COVID-19 test based on WHO recommendations, unlike the CDC. The hospital system has the capacity to conduct about 1,000 tests per day, and is working to ramp that up to 4,000 or 5,000 daily tests.

The Cleveland Clinic's test, meanwhile, should only take about eight hours to turn around a positive or negative result and should be ready by the end of March.

In a statement provided Thursday to Popular Mechanics, the Cleveland Clinic says it will soon have the capabilities to conduct on-site testing. "We are in the process of validating our testing capabilities and will soon send out more information."

Moving forward, Dr. Fichtenbaum expects the FDA to soon approve what's known as multiplex testing, which will allow labs to run 96 tests at once, rather than work with one specimen at a time.

"They need to approve that at each lab and theyre slow," says Dr. Fichtenbaum. But he anticipates the FDA will give the all-clear in the next few days. Then, it's just a matter of manufacturing the tests, which should happen rapidly.

In the meantime, community spread continues, despite self-quarantine measures, countless canceled events, and sweeping work-from-home policies. The number of positive cases is probably significantly higher than the data shows, says Dr. Fichtenbaum, which only worsens the contagion.

"I think that COVID-19 is probably more prevalent in our communities than we think," he says.

And the clinical microbiologists working tirelessly at the front lines in hospitals fully expect to meet demand. Dr. Heba Mostafa, assistant professor of pathology at Johns Hopkins University, tells Popular Mechanics that she expects to see testing ramp up and really meet demand over the course of the next four to eight weeks.

And Dr. Carroll says that the spirit of collaboration between academic medical centers has been refreshing. The University of Texas and the University of Washington have each helped out the Johns Hopkins effort, she says. They helped supply the genetic material necessary to complete their test's validation. Still, it's grueling.

"Our hospital is very happy that we went live yesterday, but of course now theyre interested in how many tests we can do," Carroll said with a laugh. "I sometimes feel that clinical microbiologists are the unsung heroes."

View original post here:

Why There Aren't Enough Coronavirus Tests in the U.S. - Popular Mechanics

UPMC ready to test for coronavirus; Collection site to open in Williamsport | News, Sports, Jobs – Lock Haven Express

UPMC has developed a test for the novel coronavirus SARS-CoV-2 the virus that causes COVID-19 and will use this test to diagnose select, symptomatic cases.

The health system plans to rapidly increase capacity at its central laboratory and, if there is a need, could test hundreds of patients per week in the near future, filling a critical gap before other commercial tests come online.

Developing this test for a never-before-seen virus in the midst of a pandemic was a tremendous challenge, even for our academic medical center with its long history of such developments, said Alan Wells, M.D., D.M.Sc., medical director of the UPMC Clinical Laboratories and Thomas Gill III Professor of Pathology at the University of Pittsburgh School of Medicine. But testing capabilities are absolutely essential to managing a pandemic. If the communities we serve see a surge in severe illnesses, we must be able to diagnose people quickly to give them the appropriate care while protecting our staff and the broader community.

Additionally, UPMC on Tuesday will begin directing patients with symptoms consistent with COVID-19 to a specimen collection site in Pittsburghs South Side neighborhood. The site is not open to the general public. Patients must have a physician referral approved by UPMCs infection prevention team and an appointment to have their specimen collected for testing by either UPMC or public health authorities.

UPMC will later open additional specimen collection facilities in Harrisburg, Erie, Williamsport and Altoona at an as-yet undetermined date after gaining experience with the South Side facility and after UPMCs testing capacity increases.

Testing capabilities for COVID-19 in the U.S. have been delayed and limited, creating anxiety for the people we serve and impairing our ability to optimally guide the public health response, said Donald Yealy, M.D., chair of emergency medicine for UPMC and Pitt. By creating our own test and collection centers, we can both help our patients and the overall community. We seek getting a diagnosis in hours, not days.

The U.S. lagged behind other countries in testing capacity, which was centered around public health authorities. The tests created by commercial laboratories are either not serving the Pittsburgh region or can take longer for results, according to Wells.

Trained UPMC providers will collect specimens, doing so safely while wearing personal protective equipment, including gowns, gloves and N95 masks or respirators. Collection will occur in negative pressure rooms, which assure that air does not leave the room until it flows through a high-efficiency particulate air (HEPA) filter that removes pathogens. The process involves a nasopharyngeal swab, a thin device inserted through a patients nose into the nasal cavity.

The specimens will be safely transported for testing to the UPMC Clinical Laboratories, the largest academic clinical lab in the U.S. In most cases, results will be returned within 24 hours. UPMC may continue to send specimens to the Pennsylvania Department of Healths laboratory in eastern Pennsylvania or health department laboratories in New York and Maryland as needed and for confirmation. UPMC will work with commercial laboratories to send specimens to them as soon as they have capacity, which will maximize the health systems ability to test all who need it.

UPMCs laboratory developed test was created using reagents already approved for making a SARS-CoV-2 test and following U.S. Centers for Disease Control and Prevention (CDC) guidelines. It is validated under the Clinical Laboratory Improvement Amendments program of the Centers for Medicare & Medicaid Services for use in human diagnoses.

The test was created by a virology team led by Tung Phan, M.D., Ph.D., assistant professor of pathology at Pitt and assistant director of clinical microbiology at UPMC; Charles Rinaldo, Jr., Ph.D., chair and professor of the Pitt Graduate School of Public Healths Department of Infectious Diseases and Microbiology and director of the UPMC Clinical Virology Laboratory; and Stephanie Mitchell, Ph.D., assistant professor of pathology at Pitt and director of clinical microbiology at UPMC Childrens Hospital of Pittsburgh. Implementation work was done by Arlene Bullotta, Barbara Harris and Kathy Greenawalt of the Section of Virology at UPMC Clinical Laboratories. This was a tireless effort by a team dedicated to serving the needs of our patients, said Wells.

The test was validated with genetic samples of SARS-CoV-2 shared by Paul Duprex, Ph.D., director of Pitts Center for Vaccine Research, which is pursuing development of a COVID-19 vaccine.

Anyone whose sample is taken should self-isolate until results come back. If it is positive, UPMC will refer the patient to public health authorities and ensure ongoing care. All positive UPMC test results will be presumed positive until confirmed by the CDC or state public health laboratories.

People who suspect they have COVID-19 but do not have a high fever or breathing problems should call their primary care physician or use UPMC AnywhereCare, an online tool to get advice. Anyone with a high fever or breathing trouble should go to their local emergency department for evaluation and care.

By CHRISTOPHER RUGABERAP Economics WriterWASHINGTON The Federal Reserve took emergency action Sunday to ...

http://www.LockHavenPa.govThe City of Lock Haven is following public health advice to take precautionary measure to ...

From Staff ReportsSenate President Pro Tempore Joe Scarnati (R-25) and Senate Majority Leader Jake Corman (R-34) ...

MILL HALL All children up to the age of 18 will be provided free breakfast and lunch meals while schools are ...

From Staff ReportsLOCK HAVEN The Clinton County commissioners issued a press release over the weekend ...

View post:

UPMC ready to test for coronavirus; Collection site to open in Williamsport | News, Sports, Jobs - Lock Haven Express

The New Game of Microbiology Clue: The Who, When, Where, and Why of the Novel Coronavirus – Psychiatric Times

Starting as a mysterious pneumonia in Wuhan, China, the newly named COVID-19 has resulted in a worldwide outbreak, causing morbidity and mortality as well as potentially disrupting the global economy. The World Health Organization (WHO) has declared this a global pandemic; to date (as this article goes to press), there are more than 80,000 reported cases worldwide (72,506 from Mainland China, Hong Kong, and Macau), and COVID-19 has claimed more than 2700 lives. (For more information, please see https://www.cdc.gov/coronavirus/ 2019-ncov/summary.html.)

Although pharmaceutical companies and countries are looking into vaccinations and curative treatment for coronavirus infection, currently there is nothing available; thus, precautions against transmission and early supportive treatment is key. Psychiatrists must have a basic understanding of the pathophysiology of coronaviruses in order to be able to accurately explain and discuss those issues with their patients, especially as mental health ramifications are expected.

Exploring the coronavirus: what is it?

Coronaviruses, belonging to the Coronaviridae family, are singlestranded positivesense ribonucleic acid (RNA) viruses that thrive in animals, which are their natural carriers. The only coronaviruses previously known to infect humans were HCoV229E, HCoVOC43, HCoVNL63, andHKU1, as well as the two infamous relatives of 2019-nCoVthe severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS), responsible for outbreaks in 2002-2003 and 2012, respectively. Alphacoronaviruses and betacoronaviruses infect mammals (eg, bats) whereas gammacoronaviruses and deltacoronaviruses are more prone to cause fish and bird infections (Table). Animal to humanzoonotictransmission is not the norm for coronaviruses, but prior coronavirus outbreaks in animals have been economically damaging.

It is unclear why more zoonotic epidemics have been occurring of late. However, it is hypothesized that global climate factors may be related and similar to viral mutations linked to pandemic capacity (ie, genetic drifts in a wide outbreak in animals may essentially lead to better virus survival rates in humans).1,2

In the case of COVID-19, the transmission is suspected to have occurred at the Wuhan Huanan Seafood Wholesale Market, although the exact carrier species has not been determined.3 From this point, the main 2019-nCoV contagion has been human-to-human transmission. Symptoms have ranged from mild to severe, with most patients reporting fever, dry cough, myalgia, fatigue, and diarrhea.4 Gastrointestinal symptoms have been present, although less frequent than with SARS.5

Variations in innate immune response

Why do some people get sicker than others? Coronaviruses have an RNA genome, similar to the influenza virus (responsible for the flu) or the respiratory syncytial virus (RSV). The immune system recognizes the RNA as foreign and triggers the immune response responsible for fighting the virus (ie, production of interferons and pro-inflammatory cytokines), and then clearing the foreign entity out of the body. A review of the exact immune responses are beyond the scope of this manuscript. However, the reader is encouraged to remember that the immune system is highly adaptable and modifies its metabolism and existing balance to fight expected threats (for an excellent review, see Kikkert6). Unfortunately, the virus exploits the hosts immune system, mimicking certain innate components to hide while replicating, which makes the immune system less able to effectively fight the invasion. Viruses may also halt cellular replication and use existing cellular resources to prioritize viral replication. The balance between immune response and viral replicative success ultimately determines disease outcome.

Certain populations are known to be vulnerable to COVID-19, such as infants, the elderly, and those with immunocompromised systems or pre-existing medical issues, who are at increased risk for severe repercussions from infections and, thus, more likely to develop sepsis and possibly death; worse outcomes could also be related to an overactive immune response.7 Cytokine storm, a term referring to over-production of inflammatory cytokines, was found more often in patients suffering from COVID-19 who ended up in intensive care, but causal factors are not fully understood.8 Thus far, there is no way to predict who will have an exaggerated immune response besides looking for the previously noted clinical, non-specific factors.

Prevention, treatment, mental health implications >

Disclosures:

Dr Moukaddam is Associate Professor, Menninger Department of Psychiatry and Behavioral Science, Baylor College of Medicine, Ben Taub Adult Outpatient Services Director, Medical Director, STAR (Stabilization, Treatment, and Rehabilitation) Program for Psychosis, Houston, TX. Dr Shah is Professor & Executive Vice Chair, Barbara & Corbin J. Robertson Jr. Chair in Psychiatry at Menninger, Chief of the Division of Community Psychiatry at Baylor College of Medicine. They report no conflicts of interest concerning the subject matter of this article.

References:

1. Caminade C, McIntyre KM, Jones AE. Impact of recent and future climate change on vector-borne diseases. Ann N Y Acad Sci. 2019;1436(1):157-173.

2. Goneau LW, Mehta K, Wong J, LHuillier AG, Gubbay JB. Zoonotic Influenza and Human Health-Part 1: Virology and Epidemiology of Zoonotic Influenzas. Curr Infect Dis Rep. 2018;20(10):37.

3. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. NEJM. 2020.

4. Liu J, Zheng X, Tong Q, et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. J Med Virol. 2020.

5. Habibzadeh P, Stoneman EK. The Novel Coronavirus: A Birds Eye View. Int J Occup Environ Med. 2020;11(2):65-71.

6. Kikkert M. Innate Immune Evasion by Human Respiratory RNA Viruses. J Innate Immun. 2020;12(1):4-20.

7. Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol. 2017;39(5):517-528.

8. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England). 2020;395(10223):497-506.

9. WHO. Use of disinfectants: alcohol and bleach. Infection prevention and control of epidemic-and pandemic-prone acute respiratory infections in health care. Geneva: WHO;2014.

10. Siddharta A, Pfaender S, Vielle NJ, et al. Virucidal Activity of World Health Organization-Recommended Formulations Against Enveloped Viruses, Including Zika, Ebola, and Emerging Coronaviruses. J Infect Dis. 2017;215(6):902-906.

11. Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and its inactivation with biocidal agents. J Hosp Infect. 2020.

12. Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DA. Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis. 2009;9(5):291-300.

13. Serrano I, Gomes D, Ramilo D, et al. An Overview of Zoonotic Disease Outbreaks and its Forensic Management Over Time. J Forensic Sci. 2019;64(5):1304-1311.

Read more here:

The New Game of Microbiology Clue: The Who, When, Where, and Why of the Novel Coronavirus - Psychiatric Times

GeneTx and Ultragenyx Announce First Patient Dosed in Phase 1/2 Clinical Trial of GTX-102 in Patients with Angelman Syndrome – BioSpace

SARASOTA, Fla. and NOVATO, Calif., March 16, 2020 (GLOBE NEWSWIRE) -- GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc.Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare diseases, today announced that it has dosed the first patient in its KIK-AS (Knockdown of UBE3A-antisense in Kids with Angelman Syndrome) study of GTX-102, an experimental antisense oligonucleotide being evaluated for the treatment of Angelman syndrome (AS).

The Phase 1/2 open-label, multiple-dose, dose-escalating study will enroll 20 patients to evaluate the safety, tolerability, and potential efficacy of GTX-102 in pediatric patients with Angelman syndrome. This is the first investigational study testing an antisense oligonucleotide as a potential therapy to treat AS. Further details can be referenced at: https://clinicaltrials.gov/ct2/show/NCT04259281.

Today is an important milestone with the dosing of the first patient in the KIK-AS study, stated Dr. Scott Stromatt, GeneTxs Chief Medical Officer GTX-102 has the potential to address the underlying deficiency that causes Angelman syndrome and we are excited, grateful and humbled to be leading this scientific quest. We look forward to the results of this study and sharing them with the Angelman community.

The GeneTx team has achieved a tremendous accomplishment rapidly advancing this program into the clinic, and GTX-102 may one day provide patients with Angelman syndrome with the first targeted therapy and a potentially transformative option for this devastating disease, said Camille L. Bedrosian, M.D., Chief Medical Officer of Ultragenyx.

Chicagos Rush University Medical Center is the first clinical site to begin enrolling patients in the KIK-AS study, with additional sites being planned in Boston, Cincinnati, Denver, Los Angeles, New York and Ottawa, Canada.

When I held the syringe with this investigational treatment in my hand to inject it for the first time, I thought about the scientific advances in genomic and molecular medicine to produce potential treatments that bring hope of changing the disease course and ameliorating severity of symptoms in those with Angelman syndrome, said Elizabeth Berry-Kravis, site principal investigator at Rush. This is an exciting time for the field of neurodevelopmental disorders as we embark on a path to understanding the outcomes of treatments directed at correcting the underlying molecular causes of disease.

Pending additional site activation, GeneTx Biotherapeutics expects to report preliminary data from the first cohorts in the study in early 2021.

About Angelman Syndrome

Angelman syndrome is a rare, neurogenetic disorder caused by loss-of-function of the maternally inherited allele of the UBE3A gene. The maternal-specific inheritance pattern of Angelman syndrome is due to genomic imprinting of UBE3A in neurons of the central nervous system, a naturally occurring phenomenon in which the maternal UBE3A allele is expressed and the paternal UBE3A is not. Silencing of the paternal UBE3A allele is regulated by the UBE3A antisense transcript (UBE3A-AS), the intended target of GTX-102. In almost all cases of Angelman syndrome, the maternal UBE3A allele is either missing or mutated, resulting in limited to no protein expression. This condition is typically not inherited but instead occurs spontaneously.

Individuals with Angelman syndrome have developmental delay, balance issues, motor impairment, and debilitating seizures. Some individuals with Angelman syndrome are unable to walk and most do not speak. Anxiety and disturbed sleep can be serious challenges in individuals with Angelman syndrome. While individuals with Angelman syndrome have a normal lifespan, they require continuous care and are unable to live independently. Angelman syndrome is not a degenerative disorder, but the loss of the UBE3A protein expression in neurons results in abnormal communications between neurons. Angelman syndrome is often misdiagnosed as autism or cerebral palsy. There are no currently approved therapies for Angelman syndrome; however, several symptoms of this disorder can be reversed in adult animal models of Angelman syndrome suggesting that improvement of symptoms can potentially be achieved at any age.

About GTX-102

GTX-102 is an investigational antisense oligonucleotide designed to target and inhibit expressionof UBE3A-AS. Nonclinical studies show that GTX-102 reduces the levels of UBE3A-AS and reactivates expression of the paternal UBE3A allele in neurons of the CNS. Reactivation of paternal UBE3A expression in animal models of Angelman syndrome has been associated with improvements in some of the neurological symptoms associated with the condition. GTX-102 has been granted Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration (FDA). InAugust 2019, GeneTx and Ultragenyx announced a partnership to develop GTX-102, with Ultragenyx receiving an exclusive option to acquire GeneTx.

About GeneTx Biotherapeutics

GeneTx Biotherapeutics LLC is a startup biotechnology company singularly focused on developing and commercializing a safe and effective antisense therapeutic for the treatment of Angelman syndrome. GeneTx was launched by FAST, a patient advocacy organization and the largest non-governmental funder of Angelman syndrome research. GeneTx licensed the rights to antisense technology intellectual property from The Texas A&M University System in December 2017.

AboutUltragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyxs strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the Company's website atwww.ultragenyx.com.

Ultragenyx Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements related to Ultragenyx's expectations regarding plans for its clinical programs and clinical studies, future regulatory interactions, and the components and timing of regulatory submissions are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, collaboration with third parties, including our partnership with GeneTx, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, such as the regulatory approval process, the timing of regulatory filings and approvals (including whether such approvals can be obtained), and other matters that could affect sufficiency of existing cash, cash equivalents and short-term investments to fund operations and the availability or commercial potential of our products and drug candidates. Ultragenyx undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Ultragenyx in general, see Ultragenyx's Annual Report filed on Form 10-K with theSecurities and Exchange CommissiononFebruary 14, 2020, and its subsequent periodic reports filed with theSecurities and Exchange Commission.

Contacts:

GeneTxPaula Evans630-639-7271Paula.Evans@GeneTxBio.com

Ultragenyx Investors & MediaDanielle Keatley415-475-6876dkeatley@ultragenyx.com

The rest is here:

GeneTx and Ultragenyx Announce First Patient Dosed in Phase 1/2 Clinical Trial of GTX-102 in Patients with Angelman Syndrome - BioSpace

Cancer Biomarker Market investigated in the latest research – WhaTech Technology and Markets News

Cancer Biomarker Market Size, Share & Trends Analysis Report by Biomarker Type (Genetic Biomarker and Protein Biomarker), By Cancer Type (Lung Cancer, Prostate Cancer, Breast Cancer, Colorectal Cancer, and Cervical Cancer), By Application (Drug Discovery & Development, Diagnosis, Risk Assessment and Prognostics), By Profiling Technology (Omics Technology, Immunoassays, Cytogenetics and Bioinformatics) and Forecast, 2019-2025

Protein biomarker is widely used in the cancer diagnosis due to various benefits such as the creation of powerful bioinformatics software, spectral libraries, and peptide databases. These benefits are creating new opportunities for developing protein biomarkers for the diagnosis, prognosis of disease and prediction of response to a therapeutic treatment.

The role of biomarkers extends all the aspects of drug discovery and development. The research of protein biomarkers includes glycosylation and phosphorylation, as it provides a clear indication of treatment with the time frame and drugs impacted on a disease.

Hence, its a decisive pathway for signaling and activation, often give insight into disease states.

Report: http://www.omrglobal.com/requesters-market

Growing research related to cancer biomarkers

The researches that are going presently have turned to the proteomics, for developing new biomarkers. These latest researches have improved the accuracy of the biomarkers as early detection of the diseases enables to provide better treatment.

Presently, scientists are also focusing on the gene expression for detecting the results of the therapy process.

Recently, the National Cancer Institute (NCI) sponsored Trial Assigning Individualized Option for treatment (Rx), or TAILORx. The National Cancer Institute in March 2016 has earmarked $5.5 million for funding for the establishment of laboratories with an aim to advance research on biomarkers and biomarker assays for various cancers such as of the prostate, lung, breast, and genitourinary organs.

The continuous interest of the government and major companies in the research and developing new technology forcancer biomarkeris motivating market growth.

The increasing trend towards personalized medicines

The increasing adoption of personalized medicines for cancer is augmenting the growth of the cancer biomarker market. Personalized medicine has the potential to modify therapy with the best response and highest safety margin to ensure better patient care.

By enabling these medicines, each patient to receive earlier diagnoses, risk assessments, and optimal treatments. The personalized medicine holds promise for improving health care while lowering costs which is expected to be a positive indicator for market growth.

As per to the Personalized Medicine Coalition (PMC), around 42% of all compounds and around 73% of oncology compounds in the pipeline have the potential to be included in personalized medicines.

The cancer biomarker companies closely doubled their R&D investment in personalized medicine over the past five years and suppose to increase their investment in the near future. Moreover, estimates of disease susceptibility or disease prognosis can be improved by combining genomic test results with knowledge about various factors such as age, lifestyle, or tumor size.

This is promising for predicting disease susceptibility, disease prognosis, or drug response of an individual patient. For device and drug manufacturers, personalized medicine provides an opportunity to develop agents that are targeted to patient groups that do not respond to medications as intended and for whom the traditional health systems have otherwise failed.

Report: http://www.omrglobal.com/industrers-market

Global Cancer Biomarker Market- Segmentation

By Biomarker Type

By Cancer Type

By Application

By Profiling Technology

Regional Analysis

North America

Europe

Asia-Pacific

Rest of the World

Report: http://www.omrglobal.com/report-ers-market

This email address is being protected from spambots. You need JavaScript enabled to view it.

Go here to see the original:

Cancer Biomarker Market investigated in the latest research - WhaTech Technology and Markets News

GW Pharmaceuticals submits Type II Variation Application to the European Medicines Agency (EMA) to expand the use of EPIDYOLEX, (cannabidiol) oral…

GW Pharmaceuticals plc (Nasdaq: GWPH) (GW, the Company or the Group), a world leader in discovering, developing and commercialising cannabinoid prescription medicines, today announces the submission of a Type II Variation Application to the European Medicines Agency (EMA) seeking approval of EPIDYOLEX, (cannabidiol) oral solution, for the treatment of seizures associated with Tuberous Sclerosis Complex (TSC), a rare genetic condition and a leading cause of genetic epilepsy. If approved, this will be the third licensed indication for GWs cannabidiol oral solution in Europe.

This submission to the EMA is an important step for GW and furthers GWs mission to bring innovative cannabinoid medicines to patients with high unmet need, said Chris Tovey, GWs Chief Operating Officer. We look forward to working with the EMA to demonstrate GWs cannabidiol oral solutions potential in this new indication and hope to make this rigorously tested cannabis-based medicine available to a new group of patients through a potential approval in due course.

TSC is a condition that causes mostly benign tumours to grow in vital organs of the body including the brain, skin, heart, eyes, kidneys and lungs, and in which epilepsy is the most common neurological feature. TSC is typically diagnosed in childhood.1

The Type II Variation Application is based on data from a positive Phase 3 safety and efficacy study. The study met its primary endpoint with patients treated with GWs cannabidiol oral solution 25 mg/kg/day experiencing a significantly greater reduction from baseline in TSC-associated seizures compared to placebo (49% vs 27%; p=0.0009). Results for the 50 mg/kg/day dose group were similar, with seizure reductions of 48% from baseline vs 26.5% for placebo (p=0.0018). All key secondary endpoints were supportive of the effects on the primary endpoint. The safety profile observed was consistent with findings from previous studies, with no new safety risks identified.

ADDITIONAL INFORMATION

About Tuberous Sclerosis Complex (TSC)Tuberous Sclerosis Complex (TSC) is a rare genetic condition that has an estimated prevalence in the EU of 10 in 100,000.2 The condition causes mostly benign tumours to grow in vital organs of the body including the brain, skin, heart, eyes, kidneys and lungs and is a leading cause of genetic epilepsy.1,3 TSC often occurs in the first year of life with patients suffering from either focal seizures or infantile spasms. It is associated with an increased risk of autism and intellectual disability.1 The severity of the condition can vary widely. In some children the disease is very mild, while others may experience life-threatening complications.4

About EPIDIOLEX/EPIDYOLEX (cannabidiol) oral solutionEPIDIOLEX/EPIDYOLEX (cannabidiol) oral solution, the first prescription, plant-derived cannabis-based medicine approved by the U.S. Food and Drug Administration (FDA) for use in the U.S. and the European Medicines Agencys (EMA) for use in Europe, is an oral solution which contains highly purified cannabidiol (CBD). EPIDYOLEX received approval in Europe in September 2019 for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older in conjunction with clobazam. In the U.S., EPIDIOLEX was approved in June 2018 by the FDA and is indicated for the treatment of seizures associated with LGS or Dravet syndrome in patients two years of age or older. A supplemental New Drug Application (sNDA) was submitted to the FDA in early 2020 for the treatment of seizures associated with Tuberous Sclerosis Complex (TSC). GWs cannabidiol oral solution has received Orphan Drug Designation from the FDA and the EMA for the treatment of seizures associated with Dravet syndrome, LGS and TSC, each of which are severe childhood-onset, drug-resistant syndromes.

About GW Pharmaceuticals plc Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercialising novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Companys lead product, EPIDIOLEX/EPIDYOLEX (cannabidiol) oral solution is commercialised in Europe by GW, and in the U.S. by the Companys subsidiary, Greenwich Biosciences. The Company has a strong pipeline of additional cannabinoid product candidates, with late-stage clinical trials in autism, schizophrenia, post-traumatic stress disorder (PTSD) and spasticity associated with multiple sclerosis (MS) and spinal cord injury. For further information, please visit http://www.gwpharm.com.

1 NIH Tuberous Sclerosis Fact Sheet. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Tuberous-Sclerosis-Fact-Sheet. 2 Prevalence and incidence or rare diseases: Bibliographic data.https://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf3 TS Alliance Website. https://www.tsalliance.org/. Accessed November 19, 2019.4 de Vries PJ, Belousova E, Benedik MP, et al. TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study. Orphanet J Rare Dis. 2018;13(1):157.5 Kwan P., Brodie M.J. Early identification of refractory epilepsy. N. Engl. J. Med. 2000;342(5):314319.6 French JA. Refractory epilepsy: clinical overview. Epilepsia. 2007;48 Suppl 1:3-7.

News by QuoteMediawww.quotemedia.com

Read the original:

GW Pharmaceuticals submits Type II Variation Application to the European Medicines Agency (EMA) to expand the use of EPIDYOLEX, (cannabidiol) oral...

Alzheimer’s Brains Short Circuited by Defective Protein Connections – Genetic Engineering & Biotechnology News

In many respects, the brain is a black box. The organ where our knowledge is derived is, ironically, also the one where much of the knowledge for its inner workings are lacking. However, researchers have devoted their lives to understanding the enigmatic organ and work tirelessly to prevent diseases that deprive it of its primary functions. For instance, new research from a team of investigators led by scientists at Memorial Sloan Kettering (MSK) has uncovered new findings that show how stress-induced changes in protein connections in the brain contribute to the cognitive decline seen in Alzheimers disease (AD).

Amazingly, the researchers were able to reverse this malfunctioning protein network and its associated cognitive decline in mice, using an experimental drug. Findings from the new studypublished recently in Nature Communications through an article entitled The epichaperome is a mediator of toxic hippocampal stress and leads to protein connectivity-based dysfunctionsuggest a new way to look at how Alzheimers develops in the brain by focusing on protein networks.

The research team used laboratory, mouse, and brain-tissue studies to examine the epichaperomea dysregulated network of proteins that affects how cells communicate and accelerate the course of disease.

To find out why epichaperomes were prevalent in Alzheimers, we used a new omics method, we call chaperomics, that allows us to assess functional outcomes of connectivity changes between normal individuals and those with Alzheimers, explained senior study investigator Gabriela Chiosis, PhD, a professor in the department of molecular pharmacology and chemistryat MSK. This new technology has a profound capacity for high throughput. Although chaperomics generates massive datasets, Chiosis states data analysis is meant to be readily accessible, indicating The bioinformatics platforms are straightforward and easy to comprehend, rather than adding additional complexity to these large protein connectivity-based results.

Various stressorssuch as genetic risk factors, vascular injury, and diabetescan damage brain circuitry in AD. According to this new study, these stressors seem to interact with proteins and contribute to toxic changes that begin in the hippocampus, a brain region involved in learning and memory. The researchers explored how these protein networks stop working properly and can be restored.

We used cellular and animal models as well as human biospecimens to show that AD-related stressors mediate global disturbances in dynamic intra- and inter-neuronal networks through pathologic rewiring of the chaperome system into epichaperomes, the authors wrote. These structures provide the backbone upon which proteome-wide connectivity, and in turn, protein networks become disturbed and ultimately dysfunctional.

Much like faulty wires in a circuit board that lead to network failure, epichaperomes seem to remodel cellular processes that, in turn, rewire protein connections supporting normal brain function. The resulting imbalance in brain circuitrywhich the authors call protein connectivity-based dysfunctionunderlies synaptic failure and other neurodegenerative processes. The researchers studied a cellular model of Alzheimers and a mouse model of the protein tau, as well as human brain tissue, which showed significantly more epichaperomes in individuals who had Alzheimers than in cognitively healthy people.

Based on their discoveries, Chiosis and her colleagues developed a new term to describe this phenomenonprotein connectivitybased dysfunction or PCBD. Many people who study Alzheimers are thinking about circuits in the brain. But theres no clear understanding of how stressors due to aging and the environment change the way proteins interact, noted collaborating scientist and study co-author Stephen Ginsberg, PhD, an associate professor at the Center for Dementia Research at the Nathan Kline Institute and departments of psychiatry, neuroscience & physiology and the NYU neuroscience institute at the NYU School of Medicine. Our research demonstrates that epichaperome formation rewires brain circuitry in Alzheimers by enabling proteins to misconnect, leading to downstream PCBD and cognitive decline.

In the current study, the research team treated young and old mice bred to have Alzheimers with an epichaperome inhibitor they developed, called PU-AD, three times per week for three to four months. The treated mice performed better on memory and learning tests than untreated mice had less tau (a protein seen in AD) and survived longer. Whats more, their brains looked like those of normal mice. PU-AD inhibited the faulty protein networks created by epichaperomes by correcting how the proteins connected and promoting nerve-cell survival.

We show at cellular and target organ levels that network connectivity and functional imbalances revert to normal levels upon epichaperome inhibition, the authors concluded. We provide proof-of-principle to propose AD is a PCBDopathy, a disease of proteome-wide connectivity defects mediated by maladaptive epichaperomes.

Read more:

Alzheimer's Brains Short Circuited by Defective Protein Connections - Genetic Engineering & Biotechnology News

New Study Shows Combining TERT Mutation Analyses With DermTech’s PLA Provides Improved Sensitivity for Detecting Melanoma With Non-invasive Patches -…

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that SKIN, the official journal of the National Society for Cutaneous Medicine, has published data showing that combining TERT DNA mutation analyses with DermTechs Pigmented Lesion Assay (the DermTech PLA) improved the test sensitivity for detecting melanoma to 97%, up from a sensitivity of 91% without TERT.

"Clinicians average 15-25 biopsies before a single melanoma diagnosis is made," said the lead author on the study, Stephanie Jackson Cullison, MD, PhD, Dermatology, University of Pittsburgh. "Biopsies cause discomfort and scarring for patients, and there is still a 17% chance of missing melanoma with this approach. Non-invasive analysis of gene expression and TERT mutations provides insight into the biological risk of a pigmented lesion without putting patients through potentially unnecessary procedures."

"This study points to the value of having additional genetic information and objective diagnostic tools to assess disease risk beyond what can be ascertained visually," said Laura K. Ferris, M.D., PhD, associate professor, Dermatology, University of Pittsburgh.

The study assessed 103 pigmented skin lesions clinically suspicious for melanoma with the objective of evaluating the expression of LINC, PRAME and select melanoma driver mutations. Samples from clinically concerning lesions, with one or more ABCDE criteria, represent both clinically-challenging borderline lesions as well as lesions at both ends of the severity spectrum. Lesions were first sampled using the DermTech PLA non-invasive adhesive patch test, and then each lesion was surgically biopsied immediately afterwards for standard histopathological diagnoses. The study shows that:

This study supports the addition of TERT to the PLA test to improve sensitivity of the test. TERT by itself has been shown by other investigators to provide a reasonable sensitivity and high specificity in differentiating benign from malignant lesions.1 The PLA plus TERT can serve as an important test to spare patients unnecessary biopsies and excisions all while enabling the detection of melanoma at the earliest stages, said John Dobak, M.D., Chief Executive Officer of DermTech.

About DermTech:

DermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTechs mission is to transform the practice of dermatology through more accurate diagnosis and treatment, and the elimination of unnecessary surgery, leading to improved patient care and lower costs. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTechs investor relations site at: http://www.dermtech.com.

This press release includes forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as expect, estimate, project, budget, forecast, anticipate, intend, plan, may, will, could, should, believes, predicts, potential, continue, and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to the performance, patient benefits and cost-effectiveness of the DermTech PLA and the market opportunity therefor. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTechs ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTechs tests; (4) the reimbursement of DermTechs tests by Medicare and private payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTechs products; (6) DermTechs ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTechs products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in (x) the Risk Factors section of the most recent Annual Report on Form 10K filed with the Securities and Exchange Commission (the SEC) by the company, and (y) other documents filed or to be filed with the SEC by the company. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

1The Genetic Evolution of Melanoma from Precursor Lesions ...." 12 Nov. 2015, https://www.nejm.org/doi/full/10.1056/NEJMoa1502583.

Link:

New Study Shows Combining TERT Mutation Analyses With DermTech's PLA Provides Improved Sensitivity for Detecting Melanoma With Non-invasive Patches -...

Pict Offshore to Expand Production of Ladder-Less Offshore Wind Access System – Offshore WIND

Pict Offshore has received a GBP 250,000 Regional Selective Assistance grant from Scottish Enterprise to expand production of the Get Up Safe (GUS) ladder-less access system at its site in Inverkeithing, Fife.

The Get Up Safe system is a motion-compensated hoist solution that enables technicians to transfer between small moving vessels and offshore wind turbines withoutturbine boat landing and ladders.

The funding is part of a wider investment by Pict Offshore to expand manufacturing at its Inverkeithing site and allows the acceleration of the development of its R&D and assembly capabilities.

According to the company, the aim is to add 13 high skilled jobs throughout 2020 and to start placing orders with the local supply chain.

We have witnessed this innovative Scottish companys growth over many years to develop a transformative product for offshore wind made in Fife and used across the world, said Head of Low Carbon Transition at Scottish Enterprise, Andy McDonald.

The network of support around Fife Energy Park is also at the heart of this project as it is host to ORE Catapults Levenmouth Demonstrator Turbine and allowed the company to test its products on the worlds most advanced open access offshore wind turbines.

Pict Offshore began developing the product in 2016, and from 2017 prototypes of the system were tested at the 7MW Levenmouth Demonstration Turbine.

rsted announced last year it had acquired a 22.5% share in the company with an aim to mature the new ladder-less access system.

Here is the original post:

Pict Offshore to Expand Production of Ladder-Less Offshore Wind Access System - Offshore WIND

Spain’s king renounces inheritance and cuts father’s income over ‘offshore fund’ – The Guardian

Spains King Felipe VI has renounced his personal inheritance from his father and stripped the former king Juan Carlos of his annual stipend after it was alleged that Felipe VI was poised to receive millions of euros from a secret offshore fund with ties to Saudi Arabia.

The statement issued by Spains royal household on Sunday evening came after a report named King Felipe as a beneficiary of an offshore fund set up by his father in 2008. At the time, Juan Carlos was still in power.

The former head of state abdicated in 2014, after a series of scandals sent his popularity plummeting. Juan Carlos, 82, had continued to receive an annual stipend from the state, however, amounting to around 194,000 (175,000) in 2018.

The alleged offshore account, named as the Lucum Foundation, held around 65m in funds that were described as a donation from the king of Saudi Arabia, according to the Sunday Telegraph. The account was set up at an office in Panama city and tied to an account with Genevas Mirabaud private bank, the report added.

An investigation by Swiss prosecutors into another offshore fund allegedly tied to Juan Carlos, named Fondation Zagatka, sparked calls this month for Spains parliament to investigate the business dealings of the former king. The push was rejected by Spains Socialists and the two main parties on the right, who argued that any such probe would be unconstitutional.

According to newspaper La Tribune de Genve, prosecutors believe the fund could be linked to kickback payments after the former monarch helped to broker business deals with Saudi Arabia while in power.

On Sunday, the statement by the Royal household noted that King Felipe became aware last year of claims that he was the beneficiary of the Lucum Foundation and subsequently swore before a notary public that he had told his father that he was renouncing any benefit from the fund. King Felipe denied any knowledge of being a beneficiary of the Zagatka fund.

Neither King Felipe nor his household had any knowledge, participation or responsibility in the alleged events, the statement noted. The statement also includes a note from the former king, stating that he had never told his son that he was the beneficiary of the two funds.

The former king had been informed of his sons decision to renounce his inheritance as well as any asset, investment or financial structure whose origin, characteristic or purpose may not be in accordance with the law or with the rectitude and integrity of the crown, the statement added.

Since taking the throne, Felipe has fought hard to regain the royal familys footing and move past the calls for a referendum on the monarchy that greeted his proclamation. The task was made more difficult after his sister, the Infanta Cristina, was caught up in a financial scandal involving her husband, the former Olympic handball player Iaki Urdangarn.

See the rest here:

Spain's king renounces inheritance and cuts father's income over 'offshore fund' - The Guardian

Can New England Hang On to Its Offshore Wind Jobs? – Greentech Media News

BOSTON Siemens Gamesa, the worlds leading supplier of offshore wind turbines, recently revealed that its considering building a $200 million blade factory in Virginias Hampton Roads region a potential cornerstone investment for the domestic supply chain.

Thats great news for the U.S. offshore wind industry, though New England officials could be forgiven for being less than thrilled with the choice of location.

An offshore wind jobs boom looks set to wash up on American shores. An analysis released this week by the American Wind Energy Association found that offshore wind could support 83,000 U.S. jobs by 2030, assuming the country builds 30 gigawatts by then and supply-chain investments are made quickly.

But where those jobs end up is still an open question. And its one that officials in New England a region that includes Massachusetts, Connecticut, Rhode Island, Maine, Vermont and New Hampshire may have reason to be nervous about.

New England is the cradle of the American offshore wind market and in many ways its spiritual home. It hosts the country's only operating project (Block Island, off Rhode Island) and its only tailor-made offshore wind port (New Bedford, Massachusetts). Many of the U.S. industry's most important companies are currently based here.

But the regions future role in the industry particularly in manufacturing looks uncertain. Waterside space is tight in southern New England, where many projects are clustered. A number of states in the Mid-Atlantic region, where the population and electricity demand are far larger, now have much higher offshore wind targets.

We do have a relatively higher labor cost, so its hard to compete with the Mid-Atlantic, said Bruce Carlisle, managing director for offshore wind at the Massachusetts Clean Energy Center, speaking last month at an industry event in Boston. MassCEC operates the states offshore wind port in New Bedford, where its hoping to see more supply chain investment.

New England has a large cluster of projects, but the Mid-Atlantic has higher offshore wind targets. (Credit: AWEA)

Massachusetts, which boasts New Englands largest offshore wind targetat 3.2 gigawatts by 2030, has chosen to emphasize low-cost power over local job creation. Thats helped to deliver headline-grabbing prices $58 per megawatt-hour in the latest round whichin turn has spurred other states to embrace offshore wind. Whether it's an approach that delivers as many jobs as the state is hoping for remains to be seen.

In its latest procurement, Massachusetts utilities chose the low-cost energy option put forward by Mayflower Wind, a joint venture of Shell and EDPR. Other proposed projects had focused more heavily on local manufacturing.

The delay of the 800-megawatt Vineyard Wind project, originally slated for completion across two phases in 2021-2022, may also alter calculations for the local supply chain. Since Vineyard was unexpectedly hit with its delay last August, Dominion Energy confirmed plans for a 2.6-gigawatt project in Virginia, while New York and New Jersey have continued to add fuel to their markets.

Carlisle said hes frequently asked whether Massachusetts should be doing more to incentivize in-state job creation through its offshore wind procurements. Speaking at the recent event hosted by the University of Delawares Special Initiative on Offshore Wind, Carlisle stressed that Mayflower Winds winning bid did come with very significant economic development commitments.

That said, if I were the one picking the procurements, would I have picked the low-cost [project]? Probably not.

The biggest rival for jobs is the Mid-Atlantic, a region that loosely stretches from New York down to Virginia. The population in those states tends to be much larger than in New England, and some of them have more waterside space for factories, laydown yards and other critical offshore wind facilities.

By and large, the Mid-Atlantic got a later start in offshore wind, or, in cases like that ofNew Jersey, saw early efforts stall out. But over the past few years, the region has embraced the market with a passion.

Last week Virginia passed legislation mandating 5.2 gigawatts of offshore wind by 2034, and even before Siemens Gamesas announcement, the state was seen as a strong contender for future factories.

New York and New Jersey, meanwhile, now have combined targets totaling 16.5 gigawatts for 2035. New Jerseys governor talks about his state getting half of its electricity from offshore wind by the 2030s. Both states are vying aggressively for jobs.

Maryland, too, looks set for an influx of investment in the port facilities around Baltimore. All told, the Mid-Atlantic now represents one of the largest future offshore wind markets in the world, making it a powerful draw for the supply chain.

The potential emergence of markets even farther south, offshore the Carolinas, adds to the lure of the Mid-Atlantic as a location for factories.

What I worry about is the demand in the Mid-Atlantic. [] If you go farther south, the wind speeds arent as good, but theyve got some pretty powerful procurements coming up, Hilary Fagan, executive vice president for business development at the Rhode Island Commerce Corporation, said onstage at the Boston event.

Even some regions without huge targets could begin to pick up jobs in the sector. Maine, for one, has no big projects in developmenttoday but is nevertheless hoping to carve out an early role in the market.

We dont think we have to wait [for our own projects] to be engaged in that, said Dan Burgess, director of the Maine governors energy office, speaking at the Boston event.

Searsport, Maine holds promise as an offshore wind port, Burgess said. Searsport is no stranger to the wind industry: Its already seen a gigawatt of turbines pass through its gatesen route to onshore projects in Maine and Vermont, he said.

Maine, at least, ispart of New England; even farther north, companies in Canada are starting to pay close attention to the market. Marine Renewables Canada, an industry group based in Halifax, Nova Scotia, held a U.S. offshore wind "readiness" workshop this week for interested Canadian companies.

Several ports in the provinces of New Brunswick and Nova Scotia could play a role, as could facilities as far away as Newfoundland. The troublesome Jones Act, which requires that any transportation of goods and equipment between American ports must be done by U.S.-flagged vessels, could work to Canadas advantage.

Elisa Obermann, executive director at Marine Renewables Canada, said the intention of Canadian companies is not "competing for potential opportunities" with American ports.Instead, the focus is looking at where there may be gaps" and how Canadian firms "could support early U.S. offshore wind projects as they ramp up," she told Greentech Media.

We have in Canada, especially in Atlantic Canada, a number of companies that have capabilities from working in related marine and offshore sectors predominately the offshore oil and gas sector.

Many in the offshore wind industry still diplomatically downplaytensions that the competition for future jobs may engender. The market looks set to go from no pie at all to a very big one, leaving lots of pieces to go around.

Unless we really screw it up, I think were all going to win," said Fagan of the Rhode Island Commerce Corporation. "If we can get the talent and supply chain here [in New England], I think we could probably benefit from the demand down there, she said of the Mid-Atlantic market.

Even if New England were to miss out on some of the big factories, it would almost certainly remain a central hub for parts of the industry, particularly white-collar jobs:developers, engineers, financiers. Last week Denmarks rsted, the worlds leading offshore wind developer, opened an innovation hub in Providence, Rhode Island.

People look at landing a blade factory or a tower facility as the ultimate goal, and yeah, it would be great, said Carlisle of the MassCEC. But lets shift our perspective a littleand look at all the engineering, innovation, R&D, all down through our marine network supply base."

"Theres going to be plenty of activity to go around," Carlisle said. "The supply chain is going to grow and take hold here. We are going to be one of the regions people are going to look to for that expertise."

Originally posted here:

Can New England Hang On to Its Offshore Wind Jobs? - Greentech Media News

The Implications of CBP’s Offshore Jones Act Changes – The Maritime Executive

The non-Jones Act crane ship Thialf working on the topsides facility at Shell's Perdido platform in the U.S. Gulf of Mexico, 2009 (file image)

By Jon Waldron 03-11-2020 05:06:00

In December, after years of debate within the offshore industry, U.S. Customs and Border Protection (CBP) issued a decision in its Customs Bulletin entitled Modification and Revocation of Ruling Letters Relating to CBPs Application of the Jones Act to the Transportation of Certain Merchandise and Equipment Between Coastwise Points (the Decision). This decision became effective on February 17. So now the question arises - how does this actually affect offshore activities going forward?

In short, the notice eliminates previous erroneous decisions that allowed non-coastwise qualified vessels to transport items that should have been considered merchandise and not vessel equipment under the Jones Act. The notice also clarifies that lifting operations may be conducted by non-Jones Act vessels.

Specifically, as discussed in more detail below, the Decision (1) broadens the definition of merchandise to make it clear that non-Jones Act vessels can no longer carry out certain offshore activities that they have performed for years under an equipment of the vessel theory, and (2) establishes a new interpretation of Lifting Operations, to specify the movements that a non-Jones Act vessel can perform, when conducting installation or decommissioning operations, which will not be considered transportation within the meaning of the Jones Act.

Background

In both 2009 and 2017, CBP published notices to revoke or modify various rulings which potentially could have overturned decades of precedent with regard to a sweeping range of offshore operations which have never been subject to the Jones Act.To be frank, CBP did not fully understand how the offshore industry operated offshore, and the proposals were potentially over broad, without CBP understanding the economic impacts on the various types of offshore operations these proposals would have adversely affected.

As a result of strong industry backlash on both occasions, the proposals were withdrawn for reconsideration. Finally, following the 2017 withdrawal, CBP undertook an intensive exchange of information with all facets of industry to fully understand how industry actually operates offshore and to fine-tune and focus its 2019 proposal on the equipment of the vessel issues and lifting operations which resulted in this fair and well-balanced Decision.

The changes in the Decision will affect:

Vessel Equipment

For decades, CBP used a Mission of the Vessel concept to justify certain subsea installation, repair, and maintenance work. This concept was incorrectly applied over broadly, which allowed non-Jones Act vessels to perform some of these activities that should have been reserved to the Jones Act fleet. The Mission of the Vessel regime was revoked by the Decision and replaced with a new Vessel Equipment interpretation. Under this interpretation, the scope of vessel equipment was narrowed to include only items, which are necessary and appropriate for the navigation, operation, or maintenance of a vessel and for the comfort and safety of the persons on board.

CBP stressed that if an item is necessary and appropriate for the operation or maintenance of a vessel, it is considered vessel equipment. Items considered necessary and appropriate for the operation of the vessel are those items that are integral to the function of the vessel and are carried by the vessel. CBP also emphasizes that the fact that an item is returned to and departs with the vessel after an operation is completed, and is not left behind on the seabed, is a factor that weighs in favor of an item being classified as vessel equipment but is not the sole determinative factor. In addition, CBP determined that other historically used rationale using the terms foreseeability, incidental to an activity, de minimis, or unforeseen, can no longer be relied on to support an interpretation of vessel equipment.

Lifting Operations

Non-Jones Act vessels have been used for decades to perform lifting operations in the offshore sector. However, in a series of three rulings issued in 2012 and 2013, CBP ruled that a movement of a crane vessel off its central axis while a topside module is suspended from its crane - in order to avoid hitting the offshore facility before unlading the topside on it - is a violation of the Jones Act. The off-axis movement of the vessel was interpreted by CBP as providing part of the transportation of the topside between a point in the U.S. and the offshore facility. This created great confusionin the industry by making virtually any lifting operation a potential violation of the Jones Act.

As a result of its discussions with industry on this point, CBP made it a priority to clarify in its Decision that lifting operations are distinct from transportation within the meaning of the Jones Act. Accordingly, offshore lifting operations now include the lifting by cranes, winches, lifting beams, or other similar activities or operations, from the time that the lifting activity begins when unlading from a vessel or removing offshore facilities or subsea infrastructure until the time that the lifting activities can be safely terminated in relation to the unlading, installation, or removal of offshore facilities or subsea infrastructure.

CBP explained that offshore lifting operations are distinct from transportation in that any lateral movement of the vessel or the item in the vicinity of the structure or facility where the item is being positioned or removed is merely subordinate to and a direct consequence of the lifting operations. CBP reasoned that this interpretation was necessitated by safety and practical concerns, including the physical demands of the lifting operations, the mitigation of risk to human life and health, and the avoidance of damage to the marine environment. Importantly, CBP confirmed that this interpretation applies to all offshore lifting operations and is not limited to heavy lifts.

Pipelaying, Drilling Related Operations and Offshore Wind Energy Facilities

CBP specifically confirmed in its Decision that CBPs existing rulings on pipelaying and cable laying remain valid and are unaffected by its Decision. In addition, while not providing similar a statement with regard to drilling, it noted that drilling ruling letters previously identified for revocation pertaining to cement, chemicals, and other consumable materials will remain in force.Several comments sought clarification regarding the impact of the Decision on the development of offshore wind energy facilities. CBP responded that any future interpretations by CBP on the application of the Jones Act to wind energy facilities or other activities will be in response to ruling requests based on specific transactions. Accordingly, it remains prudent to assume that for the most part, until CBP issues future rulings, the Jones Act applies to wind projects in much the same manner as it applies to oil and gas projects.

Pending legislation

Meanwhile, as of the time of the writing of this article, Installation Vessel legislation is pending in Congress in the form of an amendment to the coastwise laws that would create a waiver procedure for certain lifting operations that could statutorily overturn the Decision with regard to Lifting Operations as discussed above. This provision is contained in the House passed version of the Coast Guard Authorization Act of 2019 (CGAA 2019). The Senate version of this bill is silent on this point. It is unclear what action (and when) Congress will act on this bill.

In conclusion, CBP should be commended for its hard work to reach this result and future offshore activities must be conducted in accordance with the Decision. Non-Jones Act vessels must now comply with a narrower definition of what constitutes vessel equipment not subject to the Jones Act. On the other hand, non-Jones Act vessels may conduct lifting operations in accordance with the Decisions new interpretation without fear of enforcement action, because such operations are not transportation subject to the Jones Act. However, industry must closely watch what action Congress ultimately takes on the Installation Vessel provision passed by the House to determine if the Decisions interpretation of Lifting Operations will be changed.

Jon Waldronis a partner in the Maritime and International Trade practice group at Blank Rome. Heserved in the U.S. Coast Guard for 20 years, attaining the rank of commander, and was senior counsel to the Marine Spill Response Corporation, where he provided on-scene legal advice at major spill events.

The opinions expressed herein are the author's and not necessarily those of The Maritime Executive.

See the rest here:

The Implications of CBP's Offshore Jones Act Changes - The Maritime Executive

XTU architects imagines offshore oil rigs transformed into radical housing of the future – Designboom

no stranger to an unconventional project, XTU architects presents their latest fantastical proposal titled x_lands. the concept looks at life after oil, and in particular, what to do with all the offshore platforms that have been built in the last century to drill for the earths natural resources.

all images courtesy of XTU architects

mankinds appetite for these fossil fuels has had a tremendous impact on the natural environment. as the age of oil comes to an end and countries look at utilizing renewable and greener energy sources, XTU architects proposes to tackle the symbols of the oil companies: the offshore platform.

with their immense scale, oil rig structures have an interesting potential for adaption. this project imagines the industrial monoliths transformed into poetic, habitable and exotic projects, or in other words x_lands.

imagined as bubbles or containers of housing, each proposal adds lush greenery to the industrial structures, bringing a much-needed human and natural touch to the rigs. envisioned as a sustainable path for tomorrow, the project by XTU architects aims to mark a change of paradigms.

project info:

project name: x_lands

project type: concept

architect: XTU architects

designboom has received this project from our DIY submissions feature, where we welcome our readers to submit their own work for publication. see more project submissions from our readershere.

edited by: lynne myers | designboom

The rest is here:

XTU architects imagines offshore oil rigs transformed into radical housing of the future - Designboom

Planned Offshore Wind Turbines Will Have Connection To Shore Substation – CapeNews.net

At least one offshore wind turbine project will make landfall in Falmouth.

Representatives from Mayflower Wind Energy met with the Falmouth Board of Selectmen on Monday, March 9, to discuss its offshore wind project. Mayflower Wind is one of several energy providers leasing space in the Atlantic Coast Outer Continental Shelf, approximately 50 to 70 miles south of Cape Cod and 20 miles south of Nantucket.

We will have 80 to 100 wind turbines placed within a one-by-one-nautical-mile grid, said John Hartnett, president of Mayflower Wind Energy.

The project has the potential to supply 1.2 gigawatts of renewable wind energy for use by electricity customers within New England. Once constructed, the wind turbines will be connected to an offshore substation, which will connect to an onshore substation in Falmouth. The location of this substation has not been determined. This onshore substation will feed into a transmission station at Joint Base Cape Cod in Bourne.

When asked if the other energy providers are making landfall in Falmouth, Mr. Hartnett said no. Other providers have either not decided where their projects will make landfall or will be connecting to substations in Fall River or Barnstable.

Construction work is several years away.

The construction period is anticipated for 24, 25 and 26, Mr. Hartnett said. It will be at the end of 25 or early 26 before we generate power, assuming the permitting process goes as planned.

He said this project requires federal, state and local approvals, including approvals from the US Army Corps of Engineers, Bureau of Ocean Energy Management, US Coast Guard, Federal Aviation Administration, both the US and Massachusetts Environmental Protection agencies, and the Energy Facilities Siting Board.

He said the offshore wind energy project will provide low-cost energy, improve infrastructure and create 250 jobs. He also touted its green benefits.

Our project is vitally important to the climate crisis we are experiencing, Mr. Hartnett said.

He noted the group played a role in launching the Responsible Offshore Science Alliance, which will research and monitor fisheries and offshore wind interactions in federal and state waters.

We look forward to being a partner with the Town of Falmouth for the next 43 years, Mr. Hartnett said.

Selectman Susan L. Moran asked if information regarding the project was available online for the public to view. Mr. Hartnett referred people to Mayflower Winds website, http://www.mayflowerwind.com, for additional information.

Mayflower Wind is a joint venture between Shell and EDP Renewables.

See the original post:

Planned Offshore Wind Turbines Will Have Connection To Shore Substation - CapeNews.net

Offshore Cyclone Gretel is a very close call for NZ, some severe weather risks (+10 Maps) – WeatherWatch.co.nz

Cyclone Gretel is tracking towards New Zealand today with clouds thickening over the North Island and soueast winds enhancing later in the day.

Latest reliable computer modelling continues to be in agreement that Gretel will remain a serious storm with the centre just offshore from northern New Zealand as it tracks by with about Category 1 or 2 strength.

The storm is powerful and will not be falling apart before NZ very much, instead high pressure in the Tasman Sea will guide it further east of Northland, significantly reducing the chances of severe weather here. The downside? It takes with it the chances of widespread soaking rains that in one go could have ended some droughts.

Eastern Northland has some rain chances and with still over 24 hours to go the computer models may pull the storm a little closer to NZ which could see some rainfall totals lift. But its worth noting even a very slight shift further out to sea will see more dry farms and gardens see 0mm forecast.

Winds will climb well over gale around Great Barrier Island, where power cuts may be possible on Tuesday. Isolated trees down are also possible out there. Strong winds between the storm and growing high pressure will see gales developing in Cook Strait and also around the eastern Bay of Plenty ranges where gusts could climb over 100km/h.

To make sense of this all, remember WeatherWatch.co.nz has 10 day forecasts for every location in NZ and these super local forecasts now comes with hourly wind speeds and hourly (& daily) rainfall totals.

THE MAPS:12 NOON TUESDAY (ECMWF)

GFS (AMERICA)

IBM / WEATHERWATCH:

JTWC:

WeatherWatch.co.nz

Here is the original post:

Offshore Cyclone Gretel is a very close call for NZ, some severe weather risks (+10 Maps) - WeatherWatch.co.nz

Offshore Achievement Awards postponed due to virus fears – News for the Oil and Gas Sector – Energy Voice

A highlight of the UK offshore industrys social calendar has been postponed due to fears about the coronavirus spread.

The Offshore Achievement Awards were scheduled to take place at P&J Live in Aberdeen on March 19.

But the Society of Petroleum Engineers (SPE) Aberdeen Section, which organises and hosts the OAAs, has decided to reschedule the ceremony for September 10.

The organisation said: Following a series of discussions in recent days, we regret to inform you that organisers have made the decision to postpone this years Offshore Achievement Awards due to the coronavirus outbreak.

We have taken this decision based on closely monitoring advice from government, NHS Scotland and the World Health Organisation (WHO).

The ceremony was an evening we were all looking forward to, however we must ensure health and safety is our number one priority.

All table bookings will remain valid for the rescheduled ceremony on September 10th 2020.

We thank you for your understanding and are looking forward to seeing you all in September.

See original here:

Offshore Achievement Awards postponed due to virus fears - News for the Oil and Gas Sector - Energy Voice

Island Offshore wins long-term contracts for platform supply vessels – Offshore Technology

]]> The Island Commander vessel will provide offshore services to Lundin for the next three years, under new contracts. Credit: Gunder Tande Sandersen/Island Offshore Group.

Norwegian offshore vessel owner Island Offshore has secured long-term contracts and extensions for six of its platform supply vessels (PSVs) offshore north-west Europe.

Lundin Norway, a subsidiary of Lundin Petroleum, awarded contracts for three vessels to work in Norwegian waters.

The company made a three-year deal for PSV Island Commander. This vessel will continue providing back-up for drilling at the Edvard Grieg complex in the Utsira High region of the North Sea.

Lundin contracted the LNG-fuelled Island Crusader and Island Contender for durations 600 and 400 days respectively. The two LNG vessels will start work between April and August this year.

The Island Crusader will support the semi-submersible West Bollsta for a ten-well drilling programme. Meanwhile the Island Contender will assist the jack-up Rowan Vikingin drilling seven wells.

Island Offshore Management managing director Tommy Walaunet said: We have not seen contracts of equivalent duration for quite some time now, which makes it extra pleasant to sign contracts for three vessels in one go.

This provides predictability for all our employees as well as a stable income for these vessels.

As well as the Lundin deals, Island Offshore won an extension of an existing contract with Team Marine. It has retained the PSV Island Champion for another year, operating out of Aberdeen.

Walaunet added: Both vessel and crew have delivered high-quality services for years with exceptionally good feedback from the customer. We are pleased and proud to have secured this extension for Island Champion.

These contracts provide a significant contribution to our order book and secures work places to our competent crew.

Follow this link:

Island Offshore wins long-term contracts for platform supply vessels - Offshore Technology

HeliService and Nakanihon Air Service Team Up for Japan’s Offshore Wind – Offshore WIND

HeliService International has entered into long-term cooperation with the Japan-based Nakanihon Air Service for the Japanese offshore wind market.

According to HeliService, Nakanihon deems to offer helicopter offshore services in Japan and Asia as the offshore wind market is evolving in the region.

We are very pleased to have entered this deep co-operation with HeliService. With the extensive experience and expertise HeliService has in the Offshore Wind Market we regard them as our partner of choice, said Taku Shibata, President of Nakanihon Air Service.

Under the agreement, the German company will support Nakanihon in establishing offshore helicopter operations in Japan and beyond.

HeliService is honoured to support such a reputable company as Nakanihon. We are excited about the outlook in Japan and are looking forward to supporting Nakanihon in developing offshore helicopter operations, Oliver Freiland, Managing Partner at HeliService, said.

See the article here:

HeliService and Nakanihon Air Service Team Up for Japan's Offshore Wind - Offshore WIND

US offshore wind to spark jobs boom as sector invests up to $57bn: AWEA – Recharge

The US offshore wind industry along the Atlantic coast will invest as much as $57bn to install up to 30GW by 2030, and could support as many as 83,000 jobs by then, according to a new report by the American Wind Energy Association (AWEA).

Sector investment will deliver $5.5bn to $14.2bn per year in economic output by 2025 and $12.5bn to $25.4bn per year by 2030, the Washington, DC-based trade group said in its US Offshore Wind Power Economic Impact Assessment released Wednesday.

The AWEA report considers a base scenario of 20GW of operating offshore wind power by 2030 with annual 2GW deployment and domestic content increasing from 21% in 2025 to 45%. Project capital costs of $3,900/kW and annual O&M costs of $94/kW in 2025 would decline to $3,250/kW and $79/kW, respectively.

A high scenario, assumes 30GW of offshore wind is installed in 2030 with annual 3GW deployment and domestic content increasing from 32% in 2025 to 60% within five years. Project capital and annual O&M costs are the same as the base scenario.

Offshore wind is key to the future of clean energy development in the US and will add to a thriving wind power industry that already represents the largest source of renewable energy in the country, said AWEA CEO Tom Kiernan.

The five-turbine, 30MW Block Island array in Rhode Island state waters is the countrys only offshore wind facility. Now owned by Orsted, it came online in December 2016.

Since then, the states of Connecticut, Maryland, Massachusetts, New Jersey, New York, and Virginia have established targets to procure a total of 25.4GW of offshore wind capacity through 2035. They selected more than 6GW of projects as of February this year to help meet these goals.

Authors of the report note that the magnitude of economic benefits depends on three key inputs: annual offshore wind project capacity installations; domestic content of components and services required to develop, build, and operate projects and overall costs to develop them.

The domestic supply chains ability to support sector development is expected to increase over time as local manufacturers and service providers react to the new industry and global turbine OEMs look to invest in US factories, they wrote.

To date, project developers and suppliers have announced investments of $307m in port-related infrastructure, $650m in transmission infrastructure and $342m in US manufacturing facilities and supply chain development. Some of that investment awaits final corporate or regulatory approvals.

Lessons learned

The report highlights that history of the land-based wind industry in the US can provide important insights for how its offshore counterpart may grow. Thanks to technology improvements and cost reductions (and federal subsidy support), land-based wind capacity grew from 2.5GW in 2000 to more than 105.5GW at the end of 2019.

As wind farms spread across the country, so did wind-related jobs and manufacturing. In the early days, many products were imported from Europe and other global manufacturing centres. However, component manufacturers began investing heavily in domestic manufacturing facilities to serve the new, growing industry.

By 2007, 100 domestic facilities served land-based wind energy and more than 500 across 42 states manufacture parts today.

The growth of the offshore wind industry holds similar promise for US job growth, project construction and operations, and domestic manufacturing. It will also create new opportunities for port revitalisation and vessel construction, notes the report.

Even though early offshore wind projects will be concentrated along the East Coast, there is an opportunity for economic benefits to spread to other parts of the country, such as the Gulf Coast where jacket foundations were manufactured for Block Island, it adds.

AWEA estimates US offshore wind will require a diverse technical workforce spanning an estimated 74 occupations including crane operators, electricians, engineers, mechanics, offshore equipment and vessel operators, pipefitters and pile drivers.

The speed at which the industry builds projects and the degree to which manufacturing and supply chains migrate to the US will be key determinants of the industrys impact on economic output and job support. If the US offshore wind industry follows in the same general footsteps of land-based wind, the results will be significant, says the report.

AWEA's study comes as the sector hopes to gather momentum following the early setback of delays to the planned start-up of the first commercial-scale US offshore wind farm, the 800MW Vineyard project, which has been hit by permitting issues.

Continue reading here:

US offshore wind to spark jobs boom as sector invests up to $57bn: AWEA - Recharge